Relapsed or Refractory Hematologic Malignancies
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
VP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Qilu PharmaceuticalQLS2309
Vanda PharmaceuticalsTrichostatin A
Clinical Trials (2)
Total enrollment: 42 patients across 2 trials
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Start: Dec 2025Est. completion: Dec 2027
Phase 1Recruiting
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Start: Sep 2018Est. completion: Dec 202542 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 42 patients
2 companies competing in this space